4.4 Article

Factors Predicting Secondary Respiratory Morbidity Following Early-Life Respiratory Syncytial Virus Infections: Population-Based Cohort Study

Related references

Note: Only part of the references are listed.
Review Infectious Diseases

Respiratory syncytial virus prevention within reach: the vaccine and monoclonal antibody landscape

Natalie Mazur et al.

Summary: Respiratory syncytial virus (RSV) is a major cause of infant mortality and morbidity in older adults. Efforts are being made to develop RSV vaccines and immunoprophylaxis using various approaches, with 33 candidates currently in clinical development. Understanding antibody targets has led to more rational and structure-based vaccine design. An extended half-life monoclonal antibody for infants is expected to receive regulatory approval within a year. Other approaches include live-attenuated vaccines for older infants, subunit vaccines for pregnant women, and vector and nucleic acid vaccines for older adults. Ensuring access and affordability of RSV vaccines globally is a priority.

LANCET INFECTIOUS DISEASES (2023)

Article Pediatrics

Early childhood wheezing phenotypes and determinants in a South African birth cohort: longitudinal analysis of the Drakenstein Child Health Study

Carlyle McCready et al.

Summary: This study aimed to describe the developmental trajectories of childhood wheezing in South Africa and the UK. Four wheeze phenotypes were identified in the South African cohort: never, early transient, late onset, and recurrent. All-cause lower respiratory tract infection and respiratory syncytial virus infection were associated with recurrent wheeze.

LANCET CHILD & ADOLESCENT HEALTH (2023)

Article Medicine, General & Internal

Respiratory syncytial virus infection during infancy and asthma during childhood in the USA (INSPIRE): a population- based, prospective birth cohort study

Christian Rosas-Salazar et al.

Summary: This study aimed to assess the association between RSV infection and childhood asthma. The findings show that not being infected with RSV during infancy is associated with a significantly reduced risk of developing childhood asthma.

LANCET (2023)

Article Medicine, General & Internal

Bivalent Prefusion F Vaccine in Pregnancy to Prevent RSV Illness in Infants

B. Kampmann et al.

Summary: Vaccination of pregnant women with RSVpreF vaccine was effective in reducing severe RSV-associated lower respiratory tract illness in infants. The vaccine showed 81.8% efficacy within 90 days and 69.4% efficacy within 180 days. The vaccine was found to be safe for both mothers and infants.

NEW ENGLAND JOURNAL OF MEDICINE (2023)

Review Immunology

Risk Factors for Poor Outcome or Death in Young Children With Respiratory Syncytial Virus-Associated Acute Lower Respiratory Tract Infection: A Systematic Review and Meta-Analysis

Ting Shi et al.

Summary: This study provides a comprehensive report on the association between various risk factors and poor outcome or death in young children with RSV-ALRTI. More research is needed to elucidate the risk factors associated with poor outcome or death using multivariable analysis.

JOURNAL OF INFECTIOUS DISEASES (2022)

Article Multidisciplinary Sciences

Developing a prediction model to estimate the true burden of respiratory syncytial virus (RSV) in hospitalised children in Western Australia

Amanuel Tesfay Gebremedhin et al.

Summary: Respiratory syncytial virus (RSV) is a leading cause of childhood morbidity, and current estimates may underestimate the true burden. A predictive model was generated using linked records and identified predictors for RSV positivity. The model showed good predictive accuracy and suggested that the true burden of RSV may be 30-57% higher than current estimates.

SCIENTIFIC REPORTS (2022)

Article Immunology

Time-Varying Association Between Severe Respiratory Syncytial Virus Infections and Subsequent Severe Asthma and Wheeze and Influences of Age at the Infection

Xin Wang et al.

Summary: Early-life severe RSV infection is associated with an increased risk of subsequent asthma and wheeze, and this association weakens over time. The association persists for 6 years in children whose first RSV infection occurs at 6-23 months, with adjusted hazard ratios of 3.9 (95% CI, 3.1-4.9) for the first 2 years, 2.3 (95% CI, 1.6-3.2) for 2 to <4 years, and 1.9 (95% CI, 1.2-2.9) for 4 to <6 years of follow-up. In contrast, the association is only significant for the first 2 years after first RSV infection in children aged 0-6 months.

JOURNAL OF INFECTIOUS DISEASES (2022)

Article Immunology

A Retrospective Cohort Study on Infant Respiratory Tract Infection Hospitalizations and Recurrent Wheeze and Asthma Risk: Impact of Respiratory Syncytial Virus

Maarten van Wijhe et al.

Summary: Infants with RSV-associated hospitalization have a higher risk of recurrent wheeze or asthma compared to infants with other respiratory infections.

JOURNAL OF INFECTIOUS DISEASES (2022)

Article Medicine, General & Internal

Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in children younger than 5 years in 2019: a systematic analysis

You Li et al.

Summary: Respiratory syncytial virus (RSV) plays a significant role in morbidity and mortality burden globally in children aged 0-60 months, especially during the first 6 months of life and in low-income and middle-income countries. Passive immunization programs targeting RSV could have a substantial effect on reducing disease burden.

LANCET (2022)

Article Medicine, General & Internal

Nirsevimab for Prevention of RSV in Healthy Late-Preterm and Term Infants

Laura L. Hammitt et al.

Summary: A single injection of nirsevimab administered before the RSV season protected healthy late-preterm and term infants from medically attended RSV-associated lower respiratory tract infection.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

Article Immunology

Effect of Infant RSV Infection on Memory T Cell Responses at Age 2-3 Years

Tatiana Chirkova et al.

Summary: This study found that RSV infection during infancy has long-term effects on memory T cell responses in children, regardless of the severity of the infection. This may increase the risk of subsequent respiratory viral morbidity in children.

FRONTIERS IN IMMUNOLOGY (2022)

Review Public, Environmental & Occupational Health

Global burden of acute lower respiratory infection associated with human metapneumovirus in children under 5 years in 2018: a systematic review and modelling study

Xin Wang et al.

Summary: This study estimated the global burden of human metapneumovirus-associated acute lower respiratory infections in children under 5 years old. In 2018, there were an estimated 14.2 million human metapneumovirus-associated ALRI cases, 643,000 hospital admissions, and 7,700 in-hospital deaths among children younger than 5 years globally. Our findings underscore the importance of intervention strategies to improve outcomes for young infants in low and middle-income countries.

LANCET GLOBAL HEALTH (2021)

Article Multidisciplinary Sciences

Population-based serology reveals risk factors for RSV infection in children younger than 5 years

Stijn P. Andeweg et al.

Summary: RSV infection is a common occurrence in children, with the majority experiencing it before the age of 2. Age and birthdate are significant predictors of RSV infection probability, with children born in summer having a higher likelihood of infection.

SCIENTIFIC REPORTS (2021)

Review Public, Environmental & Occupational Health

Global burden of acute lower respiratory infection associated with human parainfluenza virus in children younger than 5 years for 2018: a systematic review and meta-analysis

Xin Wang et al.

Summary: This study estimated the burden of human parainfluenza virus (hPIV) in childhood acute lower respiratory infections (ALRI) globally, finding that approximately 13% of ALRI cases, 4-14% of ALRI hospital admissions, and 4% of childhood ALRI mortality were attributable to hPIV. The study revealed that infants aged 0-5 months and 6-11 months had the highest hospital admission and in-hospital death rates. Overall, these numbers indicate a potentially significant burden of hPIV in morbidity and mortality of ALRI in young children.

LANCET GLOBAL HEALTH (2021)

Article Medicine, General & Internal

Single-Dose Nirsevimab for Prevention of RSV in Preterm Infants

M. Pamela Griffin et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

Article Medicine, General & Internal

Respiratory syncytial virus-associated hospitalisations in Australia, 2006-2015

Gemma L. Saravanos et al.

MEDICAL JOURNAL OF AUSTRALIA (2019)

Article Public, Environmental & Occupational Health

Using record linkage to examine testing patterns for respiratory viruses among children born in Western Australia

F. J. Lim et al.

EPIDEMIOLOGY AND INFECTION (2017)

Article Infectious Diseases

Record linkage study of the pathogen-specific burden of respiratory viruses in children

Faye J. Lim et al.

INFLUENZA AND OTHER RESPIRATORY VIRUSES (2017)

Article Allergy

The causal direction in the association between respiratory syncytial virus hospitalization and asthma

Lone Graff Stensballe et al.

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2009)

Article Critical Care Medicine

Wheezing rhinovirus illnesses in early life predict asthma development in high-risk children

Daniel J. Jackson et al.

AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2008)

Article Health Care Sciences & Services

A decade of data linkage in Western Australia: strategic design, applications and benefits of the WA data linkage system

C. D'Arcy J. Holman et al.

AUSTRALIAN HEALTH REVIEW (2008)

Review Respiratory System

Global strategy for asthma management and prevention: GINA executive summary

E. D. Bateman et al.

EUROPEAN RESPIRATORY JOURNAL (2008)

Article Public, Environmental & Occupational Health

Research use of linked health data - a best practice protocol

CW Kelman et al.

AUSTRALIAN AND NEW ZEALAND JOURNAL OF PUBLIC HEALTH (2002)